LOKELMATM Sodium Zirconium Cyclosilicate

SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1

*In an emergency situation, standard of care should be used in line with local or national guidelines
Clinical trials with LOKELMA have not included exposure longer than one year

Clinical Studies

005 Study

LOKELMA dosing

Titrating the maintenance dose of LOKELMA can provide well-tolerated control of hyperkalaemia using the lowest effective dose for up to 12 months vs baseline serum K+ levels.4

  • Serum K+ was reduced to normokalaemic range in 66.0% of patients at 24 hours and in 77.9% of patients
    at 72 hours after initiating LOKELMA 10 g 3-times daily vs baseline serum K+ levels4,24
  • Normokalaemia was maintained for 12 months in 88.4% of patients, using the lowest effective dose of LOKELMA*24
  • LOKELMA was generally well tolerated with no new safety findings in this long-term study24
  • The extended maintenance group contained a small proportion (11%) of patients who were maintained throughout with LOKELMA 15 g once daily*24

*15 g once daily is not a licensed dose for maintenance treatment per the SmPC.

Sustained serum K+ control for up to 1 year when used as maintenance therapy1,24

Mean serum K+ levels during correction, maintenance and extension phases
Mean serum K+ levels during correction, maintenance and extension phases

Adapted from Fishbane S, et al. American Society of Nephrology Kidney Week. 2017.24

Off-drug values collected 7 (±1) days after the last administration of LOKELMA.

  • Most patients (75.3%) achieve normokalaemia within 48 hours on LOKELMA 10 g 3-times daily, but those who
    do not may still respond within 72 hours vs baseline serum K+ levels4
  • Validated the long-term (up to 12 months) safety and efficacy profile of LOKELMA in patients with hyperkalaemia
    vs baseline serum K+ levels1
  • Showed the efficacy and safety of a titrated LOKELMA maintenance dosing regimen, starting at 5 g once daily*
    for up to 12 months vs baseline serum K+ levels4
  • Presented evidence that serum K+ increased vs baseline levels after LOKELMA was stopped, confirming the need for continued serum K+ control4